{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T22:52:54Z","timestamp":1666651974068},"reference-count":16,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Diagnostik\u2002Goldstandard in der Diagnostik einer ILD bei rheumatischen Erkrankungen bleibt weiterhin die hochaufl\u00f6sende, nicht kontrastmittelverst\u00e4rkte HRCT. Verl\u00e4ssliche Biomarker f\u00fcr CTD-ILDs stehen f\u00fcr den klinischen Alltag noch nicht zur Verf\u00fcgung. Die klinisch und apparativ erhobenen Befunde lassen fast immer eine belastbare Diagnose stellen. Eine histologische Sicherung ist nur bei unklaren F\u00e4llen n\u00f6tig. Eine interessante diagnostische Option k\u00f6nnte in Zukunft die molekulare Diagnostik von Lungenparenchym sein.<\/jats:p><jats:p>\n          Therapie\u2002MTX gilt nicht l\u00e4nger als Risikofaktor f\u00fcr die Entwicklung einer chronischen ILD bzw. einer Lungenfibrose bei RA. Neuere Daten weisen darauf hin, dass MTX die Ausbildung einer ILD bei RA sogar verhindern oder zumindest verz\u00f6gern kann. In Studien bei Patienten mit SSc zeigten sich Hinweise f\u00fcr einen positiven Einfluss von Tocilizumab auf den Verlauf einer ILD mit Stabilisierung der forcierten Vitalkapazit\u00e4t in der Lungenfunktionspr\u00fcfung. Allerdings wurde der prim\u00e4re Endpunkt der Studien \u2013 Verbesserung im modifizierten Rodnan-Skin-Score \u2013 nicht erreicht. Nintedanib wurde j\u00fcngst zur Behandlung Erwachsener mit SSc-ILD sowie bei Patienten mit chronisch PF-ILD bei unterschiedlichen Grunderkrankungen (u.\u200aa. RA) zugelassen.<\/jats:p>","DOI":"10.1055\/a-1334-7479","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T22:34:30Z","timestamp":1622586870000},"page":"752-756","source":"Crossref","is-referenced-by-count":1,"title":["Rheuma und Lunge"],"prefix":"10.1055","volume":"146","author":[{"given":"Hans","family":"Bastian","sequence":"additional","affiliation":[{"name":"Abteilung Innere Medizin, Rheumatologie, Klinische Immunologie und Osteologie, Immanuel-Krankenhaus Berlin, Standort Berlin-Wannsee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[{"name":"Abteilung Innere Medizin, Rheumatologie, Klinische Immunologie und Osteologie, Immanuel-Krankenhaus Berlin, Standort Berlin-Wannsee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/art.40769","article-title":"Proceedings of the American College of Rheumatology\/Association of Physicians of Great Britain and Ireland Connective Tissue Disease\u2013Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities","volume":"71","author":"A Fischer","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1164\/rccm.202008-3189ED","article-title":"A New Piece to Help Solve the Interstitial Lung Disease Diagnostic Puzzle","volume":"203","author":"G P Cosgrove","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S2213-2600(19)30059-1","article-title":"Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study","volume":"7","author":"G Raghu","year":"2019","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s15033-020-1895-1","article-title":"Lungenmanifestationen rheumatischer Erkrankungen schon fr\u00fch mitbedenken","volume":"12","author":"A Krause","year":"2020","journal-title":"Pneumo News"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","author":"P A Juge","year":"2020","journal-title":"Eur Resp J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/rheumatology\/keaa327","article-title":"Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study","volume":"60","author":"E H Ibfelt","year":"2021","journal-title":"Rheumatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04846-1","article-title":"A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease","author":"L Li","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1055\/s-0044-100207","article-title":"Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen \u2013 klinische Sektion der DGP","volume":"72","author":"M Kreuter","year":"2018","journal-title":"Pneumologie"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","article-title":"Rituximab in connective tissue disease\u2013associated interstitial lung disease","volume":"38","author":"A C Duarte","year":"2019","journal-title":"Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"G Sircar","year":"2018","journal-title":"Rheumatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"C Fern\u00e1ndez-D\u00edaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"D Khanna","year":"2016","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"D Khanna","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"P M George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"O Distler","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"K B Highland","year":"2021","journal-title":"The Lancet Respiratory Medicine"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1334-7479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T22:35:59Z","timestamp":1622586959000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1334-7479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1334-7479","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}